Acumen Pharmaceuticals(US:ABOS) Globenewswireยท2025-11-12 12:00Core Insights - Acumen Pharmaceuticals reported strong operational progress in Q3 2025, focusing on its Phase 2 trial of sabirnetug and the Enhanced Brain Delivery program [2][5] - The company aims to translate advanced science into innovative medicines for Alzheimer's disease while maximizing shareholder value [2] - Anticipated non-clinical data in early 2026 and topline results from the ALTITUDE-AD Phase 2 study in late 2026 are expected to provide insights into the role of amyloid beta oligomers in Alzheimer's disease [2][5] Recent Highlights - The first patient is expected to be dosed in the open-label extension of the ALTITUDE-AD trial in November 2025 [6] - George Golumbeski, Ph.D., was appointed as Chairman of the Board, bringing over 30 years of biotechnology experience [6] - Acumen has exclusive rights to develop up to two candidates in partnership with JCR Pharmaceuticals for Enhanced Brain Delivery therapy [6] Financial Results - As of September 30, 2025, cash, cash equivalents, and marketable securities totaled $136.1 million, down from $166.2 million as of June 30, 2025, expected to support operations into early 2027 [5][14] - Research and Development (R&D) expenses decreased to $22.0 million in Q3 2025 from $27.2 million in Q3 2024, primarily due to reduced costs associated with the ALTITUDE-AD trial [6][14] - General and Administrative (G&A) expenses were $4.5 million for Q3 2025, down from $5.0 million in Q3 2024, attributed to lower legal and recruiting expenses [6][7] Loss and Equity - Loss from operations was $26.5 million for Q3 2025, compared to $32.3 million for Q3 2024, reflecting decreased R&D expenses [14] - Net loss for Q3 2025 was $26.5 million, down from $29.8 million in Q3 2024 [14] - Total stockholders' equity as of September 30, 2025, was $93.2 million, a decrease from $181.8 million as of December 31, 2024 [18]